MAP2K7 and embryonal rhabdomyosarcoma: Clinical studies with the RAF inhibitor regorafenib are currently ongoing in RMS (NCT01900743), while studies with the MEK inhibitor cobimetinib are underway in eRMS patients (NCT02639546).